<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 322 from Anon (session_user_id: faaea4fd1a6bcce55ff34734fa4064fd7154d313)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 322 from Anon (session_user_id: faaea4fd1a6bcce55ff34734fa4064fd7154d313)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><p class="p0">As is known to all of us, cancer is a serious disease tightly related to epigenetic changes, including a major process of great significance of epigenetic changes which is DNA methylation. In fact, in normal cells CpG islands is unmethylated, so when it comes to the accumulation of methyl groups at those sites, they will lead to consequence of gene silencing when they are found at promoter regions, of which a great instance is X inactivation. In cancer cells however, CpG islands are hypermethylated. In this case, DNA hypermethylation will lead to silencing tumor suppressor genes since they are processed at the CpG islands in promotor regions. Two well-known examples are presented. One is DNA hypermethylation in RB genes, which will result in retinoblastoma; another is colorectal cancer where CpG islands of a set of genes are frequently methylated. Also, hypermethylation of ICRs(imprinted control regions) will cause losses of imprinting. This may lead to gene overexpression.</p>
<p class="p0">In contrast to what has happened in CpG islands, the amount of DNA methylation in intergenic regions and repetitive elements is pretty high. The function of intergenic regions and repetitive elements is mainly maintaining genomic integrity, for instance, using various ways to prevent transposition. In addition, repetitive elements may also be a genome defense model. However, in cancer cells, these sites which are usually methylated are now hypomethylated. When this happens, genomic instability is expected since improper DNA methylation cannot effectively prevent genes from illegitimate recombination or transposition. Depletion of DNA methylation appears to enhance tumorigenesis.</p>
<p class="p0">From all above, we can say that research based on cancer related to aberration of DNA methylation has been made a huge progress while this field still remains tons of temporarily unsolvable questions.</p></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><p class="p0">In mammalian genome, genomic imprinting leads to monoallelic expression in the paternal genome. This difference is induced by different DNA methylation. One dominating mechanism is explained by H19/Igf2 cluster. There are four internal components and one decisive external factor which are Igf2 gene, imprinting control region(ICR), H19 promoter, enhancer and CTCF protein accordingly. On maternal genome, the ICR is unmethylated and hence available for CTCF protein to bind. Also, unmethylated status is remained at H19. The enhancers downstream at this time are not capable for activating Igf2 gene that is upstream the ICR. Of course H19 downstream the ICR is activated. On the contrast, the paternal ICR is methylated, together with methylation at the H19 promoter, therefore CTCF cannot 'insulate' its target and allow enhancers to activate Igf2 gene upstream.  </p>
<p class="p0">In Wilm's tumor, there is abnormal hypermethylation of ICR on maternal genome which brings the same effect that happens on the paternal one and hence Igf2 genes are overexpressed. As is known, the major role of Igf2 is as a growth promoting hormone during gestation. Obviously overgrowth is a huge cause responsible for the tumor. From all above, there is no wonder why abnormal imprinting is severe. </p></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><p class="p0">After scientists figured out what had caused cancer at a molecular level, specifically aberration of DNA methylation which brings epigenetic changes among genes found in cancer cells, they came up with a cutting-edge and exclusive targeting method to deal with cancer, which is using drugs that target the epigenetic machinery. Decitabine is a typical example. This kind of drug is defined as DNMT(de novo methyltransferases) inhibitors. Literally it is targeting and thereafter, blocking the DNMT responsible for DNA methylation. To be more specific, it irreversibly binds DNMTs after they are incorporated into DNA. After blocking the enzyme, CpG islands, for example, are losing redundant methyl groups, therefore, the gene down stream the promotor is active again, hence the tumor suppressor gene can act its function again. In short, this type of drug brings hope for those who struggle with myelodysplastic syndrome progressed to myelogenous leukaemia.</p></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><p class="p0">After altering DNA methylation, such as erasing the methyl groups, it is irreversibly changed, and an epigenetic status is mitotically heritable, so the effects will be enduring. And the effect act most effectively during the sensitive period which is defined as a short-lasting period that is susceptible to environmental changes and during which it is most likely to affect the epigenetic makeup. In short, it is a period that the environment has the biggest influence on it. During this time, epigenetic marks can be removed and reestablished. There are two major sensitive periods, one is primordial germ cell development, and another is preimplantation and postimplantation periods.  </p>
<p class="p0">As those therapists try to use pharmaceutical drugs, it is difficult to judge how many doses should be used for the patients, and it is critical for them to avoid side effects as much as possible. Thus, treating patients during sensitive periods will not be a wise choice since the epigenetic makeup is most susceptible, and once epigenetic layers have been changed, cells of the next generation will be affected greatly due to the mitotical heritability. Not to mention the toxicity the drug originally possesses will bring in.  </p></div>
  </body>
</html>